

# OVERACTIVE BLADDER

## Treatments covered

**Types:** Patient education | Behavioral modulation | Pharmacological management | Intradetrusor Botox, PTNS, SNS | Ligament surgery

**Stages:** Early | Middle | Late

For a complete overview of this Set, including definitions for each measure, time points for collection, and associated risk factors, visit <http://www.ichom.org/medical-conditions/overactive-bladder/>



## Details

- <sup>1</sup> Tracked via the ICIQ-OAB module
- <sup>2</sup> Tracked via the OAB-q SF
- <sup>3</sup> Tracked via the ICIQ-MLUTSsex or the ICIQ-FLUTSsex
- <sup>4</sup> Tracked via the Treatment Benefit Scale



**ICHOM**

OVERACTIVE  
BLADDER

Revised: 24. 01. 2022

ICHOM Set


# CONTRIBUTORS

For more information about the process of developing a Set of Patient-Centered Outcome Measures, visit [ichom.org/how-we-work/](http://ichom.org/how-we-work/)

## The Sponsors



## The Working Group



### Australia

George Szonyi | Sydney Local Health District  
Kate Moore | St George Hospital, University of NSW

### Canada

Adrian Wagg | University of Alberta

### Netherlands

John Heesakkers | UMC St Radboud

### New Zealand

Peter Herbison | Dunedin School of Medicine

### Sweden

Ian Milsom | Sahlgrenska University Hospital

### United Kingdom

Linda Cardozo | King's College Hospital NHS  
Nikki Cotterill | Bristol Urological Institute  
Philip Toozs-Hobson | Birmingham Women's NHS Foundation Trust

### United States

Anita Anderson\*  
Jennifer Anger | Cedars-Sinai Medical Center  
Caroline Foust-Wright | Massachusetts General Hospital  
Ann Gormley | Hitchcock Dartmouth MC  
Jessica McKinney | Marathon PT  
Abraham Morse | Boston Urogyn  
Samantha Pulliam | Massachusetts General Hospital

\*Patient representative